OncoTricks

Small vessels, late bilirubin, borrowed blood and milk, Oct 15, 2026

Pulmonary tumor thrombotic microangiopathy: the diagnosis that is usually made at autopsy

If you remember one thingCarcinoma, breathless over weeks, new pulmonary hypertension with a clean angiogram, platelets falling while D-dimer and LDH rise: say PTTM, echo today, treat the cancer in the same admission.

Why it happens

Nests of tumor cells lodge in small pulmonary arteries→Tissue factor, PDGF and VEGF are released→Intima proliferates, fibrin deposits, the vessel closes→Pulmonary hypertension + consumptive coagulopathy

The tumor is inside the vessel wall, not in the lung tissue. The emboli are microscopic and non-occlusive at first; the occlusion is the wall's reaction to them, driven by platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). That is why the angiogram shows no clot, why platelets are consumed, and why a PDGF blocker is part of the story below. Described by von Herbay in 1990 from autopsies of carcinoma patients; gastric adenocarcinoma in 59% of the reported cases, then breast and lung.

The picture, when it was reported

Share of cases with the finding, among cases that mentioned it (Godbole 2019)
Hypoxemia, 96 of 101
95%
D-dimer elevated, 36 of 38
95%
Pulmonary hypertension on echo, 59 of 66
89%
Nodules on CT, 24 of 28
86%
Thrombocytopenia, 30 of 39
77%
Systematic review of the English-language literature to mid-2018: 79 publications, 160 patients. Each bar counts only the cases that reported the finding at all, so for the labs and the CT that is 28 to 39 patients, not 160. Dyspnea 94%, cough 85%, anemia 84%, ground-glass 82% in the same way. Average right ventricular systolic pressure on echo, 71 mmHg. 79% of the diagnoses were made after death.
LungsBreathless over 3 weeks to 6 months, then fast. Dry cough. Oxygen need out of proportion to the scan. Loud second heart sound, raised neck veins.
BloodPlatelets falling. LDH and D-dimer up. Anemia, sometimes with fragments on the smear. Fibrinogen may be normal: this is a compensated, slow consumption, thrombotic more than bleeding.
ScanNo filling defect. Dilated pulmonary trunk. Centrilobular nodules in a tree-in-bud pattern, septal lines, patchy ground-glass, hilar and mediastinal nodes. Lymphangitic spread looks the same and can coexist.

PTTM, as a checklist: Pressure, Thrombocytopenia, Tree-in-bud, Mucinous carcinoma.Pulmonary hypertension on the echo, platelets falling, centrilobular nodules on the CT, a mucin-producing adenocarcinoma. Four letters, four findings; three of them in a cancer patient with a clean angiogram is enough to act.

From the scan to the name

1. CT angiogram for a breathless cancer patient: no embolus
look again
Do not file it as "negative"Measure the pulmonary trunk: 29 mm or wider than the aorta beside it is dilated. Tree-in-bud nodules and septal thickening in a cancer patient with a clean angiogram are the radiologist telling you.
then
2. Is there pulmonary hypertension?
echo today
Right ventricular pressure, right ventricular size, BNPNew pulmonary hypertension in a carcinoma patient with a clean angiogram is the central finding. In the authors' own series the echo came a median of 5 days after presentation; the two longest delays were outpatients.
then
3. Is the blood being consumed?
same draw
Smear, LDH, D-dimer, fibrinogen, haptoglobin, reticulocytesMicroangiopathic hemolysis or disseminated intravascular coagulation is present in about half at presentation. A normal smear does not exclude it.
confirm without cutting the lung
4. Wedged pulmonary artery catheter, aspirate the blood, send for cytologyHeparinized tube, centrifuge, examine the buffy coat. Reported sensitivity 80 to 88% and specificity 82 to 94%, from older tumor-embolism series: it proves tumor in the vessels, not the microangiopathy itself, which is enough to act on. The sample must be wedged, or cells from the liver contaminate it. A ventilation-perfusion scan with many small mismatched defects supports the diagnosis. Lung biopsy in a patient with pulmonary hypertension and a straining right ventricle is the test both reviews advise against; transbronchial biopsy has made the diagnosis in patients without pulmonary hypertension.

Why the week matters

Median 3 weeks from first symptom to death.96 reported cases with the interval known (Godbole 2019); the average was 9.5 weeks because of a few long survivors. Nobody has measured the delay from diagnosis to treatment, but with a median course of three weeks, a clinic slot in two weeks is most of the survival.

1
Treat the cancer in the same admission. Fewer tumor cells, less growth factor, less intimal proliferation. Poor performance status here is the disease.
2
Imatinib. Blocks the PDGF receptor. In five reported cases with the pulmonary pressure measured before and after, it fell in all five; four lived 7 to 13 months, the fifth about a month. Doses were 100 to 200 mg daily (one started at 50 and was titrated up, one went to 400 once the pressure fell), with chemotherapy for the primary in four of the five. Case reports show falling serum PDGF, falling BNP and reperfusion on the ventilation-perfusion scan. Oral, available the same day. Off label.
3
Dexamethasone and oxygen. Dexamethasone 0.05 mg/kg daily was part of the one reported durable remission, with chemotherapy, warfarin and aspirin; steroids cleared the ground-glass in another case. Lymphangitic spread can coexist and shares the treatment.
4
Anticoagulation only with a normal fibrinogen and no bleeding. Thrombolysis did nothing. Pulmonary vasodilators alone: the disease progressed in the reported cases; the improvements were all in combination with imatinib and chemotherapy. Imatinib with anticoagulation caused subdural bleeds in the pulmonary hypertension trials; with platelets already falling, the combination is a daily decision, not a standing order.
5
Say the prognosis out loud on day one. Palliative care in the same conversation as the treatment plan, because the median is three weeks and the treatment is a bet.
Sources

Retrieved from PubMed, read on Oct 15, 2026.

  1. Godbole RH, Saggar R, Kamangar N. Pulmonary tumor thrombotic microangiopathy: a systematic review. Pulm Circ 2019. doi:10.1177/2045894019851000
  2. Price LC, Wells AU, Wort SJ. Pulmonary tumour thrombotic microangiopathy. Curr Opin Pulm Med 2016. doi:10.1097/MCP.0000000000000297
  3. von Herbay A, et al. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer 1990. doi:10.1002/1097-0142(19900801)66:3<587::aid-cncr2820660330>3.0.co;2-j
  4. Minatsuki S, et al. Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy. Int Heart J 2015. doi:10.1536/ihj.14-220
  5. Chinen K, et al. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract 2010. doi:10.1016/j.prp.2010.05.002